FDMT 最新10-Q变化
将 FDMT 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-13 与上一份 10-Q · 2026-05-07
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +15 | −14 | ~19 | 42 |
| 市场风险(第3项) | 文字有新增/删除 | +1 | 0 | ~1 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~1 | 2 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 部分风险因素更新 | +20 | −54 | ~37 | 533 |
| 其他信息 | 文字有新增/删除 | +1 | −3 | 0 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-13
Additionally, in June 2025, we initiated 4FRONT-2, our second Phase 3 trial of 4D-150 in wet AMD. 4FRONT-2 is a global clinical trial and enrolled both treatment-naïve and recently diagnosed, treatment-experienced patients. We completed enrollment for 4FRONT-2 in June 2026 ahead of schedule with >50…
Research and development expenses increased by $44.6 million, or 50%, from the six months ended June 30, 2025 to the six months ended June 30, 2026. The increase of $44.6 million was primarily due to an increase in clinical trial activity for wet AMD.
General and administrative expenses increased by $1.0 million, or 9%, from the three months ended June 30, 2025 to the three months ended June 30, 2026. General and administrative expenses decreased by $0.2 million, or 1%, from the six months ended June 30, 2025 to the six months ended June 30, 2026…
Other income, net, decreased by $0.7 million, or 15%, from the three months ended June 30, 2025 to the three months ended June 30, 2026. Other income, net, decreased by $1.5 million, or 14%, from the six months ended June 30, 2025 to the six months ended June 30, 2026. The decreases were primarily b…
As of June 30, 2026, we had cash, cash equivalents and marketable securities of $430.6 million. We have funded our operations primarily through the sale and issuance of our equity securities, including Follow-on Offerings and our “at-the-market” offering program, from borrowings under our Loan and S…
相对上期删除的文字 · 来源:10-Q · 2026-05-07
Additionally, 4FRONT-2, our second Phase 3 trial of 4D-150 in wet AMD, was initiated in June 2025. 4FRONT-2 is a global clinical trial and is enrolling both treatment-naïve and recently diagnosed, treatment-experienced patients. We expect to complete enrollment for 4FRONT-2 in the second half of 202…
choose. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.
On July 2, 2025, we announced a workforce reduction of approximately 25% of current and planned roles, primarily in the areas supporting early-stage research and development and support functions following a strategic pipeline prioritization to focus on the development of 4D-150 and 4D-710. In conne…
General and administrative expenses decreased by $1.2 million, or 10%, from the three months ended March 31, 2025 to the three months ended March 31, 2026. The decrease was primarily due to decreased headcount of general and administrative personnel.
Other income, net, decreased by $0.8 million, or 14%, from the three months ended March 31, 2025 to the three months ended March 31, 2026. The decrease was primarily due to lower market yields on our cash equivalents and marketable securities.
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-08-13
As of June 30, 2026, we had $20.0 million outstanding under our Loan and Security Agreement, which bears interest at a floating rate. A hypothetical 75 basis point increase in interest rates would increase our annual interest expense by approximately $0.2 million, assuming the outstanding principal …
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-08-13
As of June 30, 2026, we had $430.6 million in cash and cash equivalents and marketable securities.
Due to the significant resources required for the development of our product candidates, in particular our product candidates in IND-enabling studies and those in clinical trials, we must decide which product candidates and indications to pursue and advance and the amount of resources to allocate to…
Our loan and security agreement with Hercules contains operating and financial covenants that may restrict our business and financing activities, is secured by substantially all of our assets, including our intellectual property, and we may be required to repay our outstanding indebtedness earlier t…
In June 2026, we entered into a loan and security agreement (the "Loan Agreement") with Hercules Capital, Inc. (“Hercules”), which provides for term loans in an aggregate principal amount of up to $200.0 million, of which $20.0 million was funded at closing. The term loans bear interest at floating …
The Loan Agreement contains customary affirmative and restrictive covenants that, among other things, limit our ability to transfer or dispose of assets, merge with other companies or consummate certain changes of control, make investments, incur additional indebtedness and liens and enter into new …
相对上期删除的文字 · 来源:10-Q · 2026-05-07
quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.
our early-stage research projects, continue preclinical and clinical development of our product candidates and, in particular, advance our product candidates through clinical trials. Even if we are successful in developing our product candidates, obtaining regulatory approvals and launching and comm…
As of March 31, 2026, we had $457.6 million in cash and cash equivalents and marketable securities.
Due to the significant resources required for the development of our product candidates, in particular our product candidates in IND-enabling studies and those in clinical trials, we must decide which product candidates and indications to pursue and advance and the amount of resources to allocate to…
resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain…
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-08-13
During the fiscal quarter ended June 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy…
相对上期删除的文字 · 来源:10-Q · 2026-05-07
During the fiscal quarter ended March 31, 2026, the following officer, as defined in Rule 16a-1(f), adopted a “Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, as follows:
On January 9, 2026, David Kirn, M.D., our President and Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement providing for the potential sale from time to time of up to 450,000 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10…
None of our other directors or officers (as defined in Section 16 of the Exchange Act adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 t…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议